Chemomab Therapeutics Ltd
For the period ended Oct 11, 2024. Filed Oct 11, 2024.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 11, 2024 · Filed Oct 11, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · NOTES:
NOTES:
| 1. | Please direct the Depositary how it is to vote by placing an “X” in the appropriate box opposite each agenda item. |
PROXY TABULATOR FOR CHEMOMAB THERAPEUTICS LTD. P.O. BOX 8016 CARY, NC 27512-9903
IMPORTANT NOTE: BY EXECUTING THIS PROXY CARD, THE UNDERSIGNED SHAREHOLDER IS CONFIRMING THAT HE, SHE OR IT DOES NOT HAVE A CONFLICT OF INTEREST (I.E., THE UNDERSIGNED IS NOT AN “INTERESTED SHAREHOLDER”) IN THE APPROVAL OF PROPOSAL 1 AND CAN THEREFORE BE COUNTED TOWARDS OR AGAINST THE MAJORITY REQUIRED FOR APPROVAL OF THAT PROPOSAL. IF YOU HAVE SUCH A CONFLICT OF INTEREST IN THE APPROVAL OF PROPOSAL 1, PLEASE NOTIFY MS. SIGAL FATTAL, CHIEF FINANCIAL OFFICER, AT C/O CHEMOMAB THERAPEUTICS LTD., KIRYAT ATIDIM, BUILDING 7, TEL-AVIV, ISRAEL, TELEPHONE: + 972-77-331-0156, OR BY EMAIL (SIGAL.FATTAL@CHEMOMAB.COM).
PLEASE SEE THE COMPANY’S PROXY STATEMENT FOR A FURTHER EXPLANATION AS TO WHO IS CONSIDERED AN “INTERESTED SHAREHOLDER”.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.